Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts ...
Multi-year effort leverages Muna's all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for ...
IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics ...
Studies will assess ST-067 in acute myeloid leukemia or myelodysplastic syndrome and in multiple myeloma. Preclinical data to be presented at the 2024 American Society of Hematolo ...
MELBOURNE, Australia I 4, 2024 I Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company ...
LONDON, UK I 04, 2024 I GSK plc (LSE/NYSE: GSK) and Medicines for Malaria Venture (MMV) announced today that the World Health Organization (WHO) has ...
BERLIN, Germany I 4, 2024 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...
BIRMINGHAM, AL, USA I 4, 2024 I Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in ...
PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the ...
Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target ...
Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed ...
Rgenta to receive a cash upfront and pre-option milestone payments Rgenta has the potential to receive milestone payments, royalties, and a future equity investment WOBURN, MA, USA I RNA-Targeted ...